

# Amir T Fathi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1639097/publications.pdf>

Version: 2024-02-01

189  
papers

7,141  
citations

66234

42  
h-index

64668

79  
g-index

189  
all docs

189  
docs citations

189  
times ranked

7834  
citing authors

#	ARTICLE	IF	CITATIONS
1	Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2017, 130, 722-731.	0.6	1,173
2	Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. <i>Cancer Cell</i> , 2020, 38, 79-96.e11.	7.7	389
3	Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 721-749.	2.3	314
4	Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. <i>Blood</i> , 2019, 133, 676-687.	0.6	262
5	Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2042-2048.	2.0	219
6	NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 16-27.	2.3	170
7	Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3<sup>ITD</sup> acute myeloid leukaemia in first complete remission. <i>British Journal of Haematology</i> , 2016, 175, 496-504.	1.2	162
8	Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2. <i>JAMA Oncology</i> , 2018, 4, 1106.	3.4	157
9	The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. <i>Therapeutic Advances in Hematology</i> , 2014, 5, 65-77.	1.1	151
10	A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. <i>Blood</i> , 2018, 131, 387-396.	0.6	131
11	Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. <i>Blood Advances</i> , 2020, 4, 1894-1905.	2.5	129
12	Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. <i>Experimental Hematology</i> , 2014, 42, 247-251.	0.2	125
13	Development and Validation of a Novel Acute Myeloid Leukemiaâ€œComposite Model to Estimate Risks of Mortality. <i>JAMA Oncology</i> , 2017, 3, 1675.	3.4	125
14	Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. <i>Blood</i> , 2021, 137, 1792-1803.	0.6	123
15	Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 57-65.	0.8	118
16	Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. <i>Blood</i> , 2012, 120, 4649-4652.	0.6	116
17	Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , 2018, 2, 923-932.	2.5	114
18	Health care utilization and end-of-life care for older patients with acute myeloid leukemia. <i>Cancer</i> , 2015, 121, 2840-2848.	2.0	113

#	ARTICLE	IF	CITATIONS
19	The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , 2018, 2, 1765-1772.	2.5	100
20	New directions for emerging therapies in acute myeloid leukemia: the next chapter. <i>Blood Cancer Journal</i> , 2020, 10, 107.	2.8	96
21	Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1079-1109.	2.3	96
22	Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia. <i>JAMA Oncology</i> , 2021, 7, 238.	3.4	90
23	Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 12-23.	0.8	75
24	Mutations in Epigenetic Modifiers in Myeloid Malignancies and the Prospect of Novel Epigenetic-Targeted Therapy. <i>Advances in Hematology</i> , 2012, 2012, 1-12.	0.6	73
25	Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. <i>Lancet Haematology</i> , 2020, 7, e309-e319.	2.2	70
26	AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies. <i>Blood</i> , 2014, 124, 115-115.	0.6	69
27	The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia. <i>European Journal of Haematology</i> , 2017, 98, 330-336.	1.1	68
28	Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. <i>Blood</i> , 2019, 134, 678-687.	0.6	65
29	High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. <i>Blood</i> , 2018, 131, 2816-2825.	0.6	64
30	Isocitrate Dehydrogenase 1 (IDH1) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate. <i>Oncologist</i> , 2014, 19, 602-607.	1.9	61
31	A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. <i>Blood</i> , 2018, 132, 1125-1133.	0.6	60
32	Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial. <i>Blood</i> , 2015, 126, 323-323.	0.6	57
33	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , 2020, 7, e601-e612.	2.2	56
34	Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. <i>Oncologist</i> , 2019, 24, 247-254.	1.9	55
35	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. <i>Leukemia</i> , 2020, 34, 3149-3160.	3.3	54
36	Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. <i>Blood Advances</i> , 2017, 1, 2032-2040.	2.5	53

#	ARTICLE	IF	CITATIONS
37	Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions. <i>Blood</i> , 2018, 132, 560-560.	0.6	51
38	A potential therapeutic target for FLT3-ITD AML: PIM1 kinase. <i>Leukemia Research</i> , 2012, 36, 224-231.	0.4	50
39	FLT3 inhibitor-induced neutrophilic dermatosis. <i>Blood</i> , 2013, 122, 239-242.	0.6	46
40	Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia. <i>Seminars in Hematology</i> , 2015, 52, 165-171.	1.8	44
41	Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. <i>Leukemia</i> , 2019, 33, 2393-2402.	3.3	44
42	Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016, 128, 343-343.	0.6	44
43	Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 414-423.	2.3	44
44	Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 7-8.	0.6	43
45	Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3425-3434.	1.0	40
46	AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo. <i>Blood</i> , 2014, 124, 3734-3734.	0.6	38
47	Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study. <i>Blood</i> , 2019, 134, 643-643.	0.6	37
48	Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study. <i>Blood</i> , 2015, 126, 1306-1306.	0.6	36
49	Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 591-591.	0.6	35
50	Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study. <i>Cancer</i> , 2017, 123, 2561-2569.	2.0	33
51	Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 719-727.	1.7	33
52	Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 661-668.	1.2	31
53	Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , 2018, 132, 561-561.	0.6	30
54	Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma. <i>Blood</i> , 2014, 124, 963-963.	0.6	29

#	ARTICLE	IF	CITATIONS
55	SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML. <i>Blood</i> , 2015, 126, 454-454.	0.6	29
56	Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia. <i>Blood Advances</i> , 2020, 4, 3136-3140.	2.5	28
57	Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 580-597.	0.2	28
58	Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1. <i>Blood</i> , 2016, 128, 1070-1070.	0.6	28
59	Treatment of FLT3-ITD acute myeloid leukemia. <i>American Journal of Blood Research</i> , 2011, 1, 175-89.	0.6	28
60	Acute Leukemia is Associated with Cardiac Alterations before Chemotherapy. <i>Journal of the American Society of Echocardiography</i> , 2017, 30, 1111-1118.	1.2	27
61	Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014, 124, 623-623.	0.6	27
62	Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 387-400.	0.6	26
63	A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 324-324.	0.6	26
64	Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2017, 130, 639-639.	0.6	26
65	Bone marrow response as a potential biomarker of outcomes in glioblastoma patients. <i>Journal of Neurosurgery</i> , 2017, 127, 132-138.	0.9	25
66	A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 211-211.	0.6	24
67	Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. <i>Cancer</i> , 2016, 122, 2379-2388.	2.0	23
68	Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions. , 2017, 177, 123-128.		23
69	Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. <i>Cancer</i> , 2018, 124, 306-314.	2.0	23
70	Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 541-549.	2.0	23
71	Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. <i>Blood Advances</i> , 2020, 4, 106-111.	2.5	23
72	Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 590-590.	0.6	23

#	ARTICLE	IF	CITATIONS
73	Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , 2018, 132, 1812-1812.	0.6	22
74	Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial. <i>Blood</i> , 2017, 130, 726-726.	0.6	20
75	Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. <i>Lancet Haematology</i> , 2016, 3, e276-e283.	2.2	19
76	Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e122-e133.	2.2	19
77	Emergence of crenolanib for FLT3-mutant AML. <i>Blood</i> , 2013, 122, 3547-3548.	0.6	18
78	A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database. <i>Leukemia and Lymphoma</i> , 2016, 57, 1-4.	0.6	18
79	Very Fast, High-Performance 5-2 and 7-2 Compressors in CMOS Process for Rapid Parallel Accumulations. <i>IEEE Transactions on Very Large Scale Integration (VLSI) Systems</i> , 2020, 28, 1403-1412.	2.1	18
80	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. <i>Blood</i> , 2016, 128, 216-216.	0.6	18
81	Inhibition of Phosphorylation of ERK in CLL Cells Pre-Treatment Correlates Best with Response to Dasatinib, Fludarabine, and Rituximab for Patients with Relapsed CLL. <i>Blood</i> , 2014, 124, 3636-3636.	0.6	18
82	Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , 2019, 134, 4254-4254.	0.6	17
83	A phase 1 study of the antibody-drug conjugate brentuximab vedotin with induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 1264-1273.	2.0	15
84	Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1220-1225.	0.6	15
85	Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 186-192.	1.2	14
86	Posttraumatic stress disorder symptoms in patients with acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 2500-2506.	2.0	14
87	Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , 2017, 130, 725-725.	0.6	14
88	Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation. <i>Current Cancer Drug Targets</i> , 2020, 20, 490-500.	0.8	14
89	Phase I and Expansion Study of Eprenetapopt (APR-246) in Combination with Venetoclax (VEN) and Azacitidine (AZA) in TP53-Mutant Acute Myeloid Leukemia (AML). <i>Blood</i> , 2021, 138, 3409-3409.	0.6	14
90	CMOS implementation of a fast 4-2 compressor for parallel accumulations. , 2012, , .		12

#	ARTICLE	IF	CITATIONS
91	A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, 254-261.	2.0	12
92	Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 735-746.	2.0	12
93	Palliative care and coping in patients with acute myeloid leukemia: Mediation analysis of data from a randomized clinical trial. <i>Cancer</i> , 2021, 127, 4702-4710.	2.0	12
94	A First-In-Human Phase 1 Study Of The Antibody-Drug Conjugate SGN-CD19A In Relapsed Or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma. <i>Blood</i> , 2013, 122, 1437-1437.	0.6	12
95	Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E59-E63.	2.0	11
96	T Cell Exhaustion and Downregulation of Cytotoxic NK Cells – an Immune Escape Mechanism in Adult Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3781-3781.	0.6	11
97	A Novel and Very Fast 4-2 Compressor for High Speed Arithmetic Operations. <i>IEICE Transactions on Electronics</i> , 2012, E95.C, 710-712.	0.3	10
98	New Molecular Abnormalities and Clonal Architecture in AML: From Reciprocal Translocations to Whole-Genome Sequencing. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e334-e340.	1.8	10
99	Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. <i>Cancer</i> , 2019, 125, 3845-3852.	2.0	10
100	Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 479.e1-479.e7.	0.6	10
101	High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine. <i>Blood</i> , 2019, 134, 2706-2706.	0.6	10
102	Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 766-766.	0.6	9
103	Prior cytopenia predicts worse clinical outcome in acute myeloid leukemia. <i>Leukemia Research</i> , 2015, 39, 1034-1040.	0.4	8
104	Impact of lenalidomide use among non-transfusion dependent patients with myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018, 93, 1119-1126.	2.0	8
105	Induction chemotherapy in acute myeloid leukaemia. <i>Current Opinion in Hematology</i> , 2018, 25, 67-74.	1.2	7
106	Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with FLT3-ITD AML. <i>Blood</i> , 2014, 124, 671-671.	0.6	7
107	Hematopoietic Cell Transplantation with or without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1. <i>Blood</i> , 2015, 126, 864-864.	0.6	7
108	Coping strategies in patients with acute myeloid leukemia. <i>Blood Advances</i> , 2022, 6, 2435-2442.	2.5	7



#	ARTICLE	IF	CITATIONS
109	Monoclonal Antibodies in Acute Myeloid Leukemia—Are We There Yet?. <i>Cancer Journal (Sudbury, Mass)</i> 11, 107-114. doi:10.7843/107-114	1.0	7
110	Low latency, glitch-free booth encoder-decoder for high speed multipliers. <i>IEICE Electronics Express</i> , 2012, 9, 1335-1341.	0.3	6
111	Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1754-1758.	2.0	6
112	Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2597-2597.	0.6	6
113	Ultra High Speed Modified Booth Encoding Architecture for High Speed Parallel Accumulations. <i>IEICE Transactions on Electronics</i> , 2012, E95.C, 706-709.	0.3	5
114	The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 165-174.	1.2	5
115	Lenalidomide combined with mismatched microtransplantation for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E331-E333.	2.0	5
116	First Reported Case of Invasive Cutaneous <i>Penicillium cluniae</i> Infection in a Patient With Acute Myelogenous Leukemia: A Case Report and Literature Review. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab265.	0.4	5
117	The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort. <i>Blood</i> , 2016, 128, 1063-1063.	0.6	5
118	Chemotherapy Resistance in B-ALL with Cryptic <i>NUP214-ABL1</i> Is Amenable to Kinase Inhibition and Immunotherapy. <i>Oncologist</i> , 2022, 27, 82-86.	1.9	5
119	Pevonedistat, a new partner for 5-azacitidine. <i>Blood</i> , 2018, 131, 1391-1392.	0.6	4
120	Incident adverse events following therapy for acute promyelocytic leukemia. <i>Leukemia Research Reports</i> , 2018, 9, 79-83.	0.2	4
121	Generalized Method of Analog Circuit Characteristic Function Analysis. <i>IEEE Transactions on Circuits and Systems II: Express Briefs</i> , 2019, 66, 172-176.	2.2	4
122	Glasdegib with Low-Dose Cytarabine: A New Upfront Option for the Vulnerable AML Patient. <i>Clinical Cancer Research</i> , 2019, 25, 6015-6017.	3.2	4
123	Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2019, 60, 3058-3062.	0.6	4
124	Incidence of Invasive Fungal Infections in Acute Myeloid Leukemia Without Antifungal Prophylaxis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e883-e889.	0.2	4
125	Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 545-545.	0.6	4
126	A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 340-340.	0.6	4



#	ARTICLE	IF	CITATIONS
127	Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort. <i>Blood</i> , 2018, 132, 4040-4040.	0.6	4
128	Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study. <i>Blood</i> , 2021, 138, 1521-1521.	0.6	4
129	Case 24-2012. <i>New England Journal of Medicine</i> , 2012, 367, 552-563.	13.9	3
130	Case 37-2016. <i>New England Journal of Medicine</i> , 2016, 375, 2273-2282.	13.9	3
131	Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, e70-e72.	0.8	3
132	Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 988-991.	0.6	3
133	Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy. <i>Leukemia</i> , 2020, 34, 3050-3054.	3.3	3
134	Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses. <i>Blood</i> , 2019, 134, 541-541.	0.6	3
135	Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults. <i>Leukemia and Lymphoma</i> , 2022, 63, 1428-1435.	0.6	3
136	Factors Associated with Health Care Utilization at the End of Life for Patients with Acute Myeloid Leukemia. <i>Journal of Palliative Medicine</i> , 2022, 25, 749-756.	0.6	3
137	Clustered incidence of adult acute promyelocytic leukemia. <i>Leukemia Research</i> , 2018, 74, 47-50.	0.4	2
138	A new high speed and low power decoder/encoder for Radixâ€4 Booth multiplier. <i>International Journal of Circuit Theory and Applications</i> , 2021, 49, 2199-2213.	1.3	2
139	A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML. <i>Blood Advances</i> , 2021, 5, 2279-2283.	2.5	2
140	A Phase I Study of the Aurora a Kinase Inhibitor Alisertib in Combination with 7+3 Induction Chemotherapy in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 119-119.	0.6	2
141	Intensified Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): A Phase II Study from the Dana Farber Cancer Institute (DFCI) ALL Consortium. <i>Blood</i> , 2014, 124, 3714-3714.	0.6	2
142	Outcomes for Older Patients with Acute Myeloid Leukemia Admitted to the Intensive Care Unit. <i>Blood</i> , 2015, 126, 2104-2104.	0.6	2
143	A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 5218-5218.	0.6	2
144	Design and performance analysis of an ultraâ€highâ€speed 5â€2 compressor. <i>International Journal of Circuit Theory and Applications</i> , 2022, 50, 1576-1588.	1.3	2

#	ARTICLE	IF	CITATIONS
145	CD30: a new target for ALL?. <i>Leukemia and Lymphoma</i> , 2014, 55, 478-479.	0.6	1
146	Molecular Characterization of Clinical Response and Relapse in Patients with <i>IDH1</i> -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine. <i>Blood</i> , 2020, 136, 49-51.	0.6	1
147	A Comparative Retrospective Survey of Reinduction Chemotherapy Regimens for Acute Myeloid Leukemia (AML) in First Relapse: A Single-Institution Experience. <i>Blood</i> , 2011, 118, 4273-4273.	0.6	1
148	Trends In Outcomes In Core Binding Factor Acute Myeloid Leukemia: A SEER Database Analysis. <i>Blood</i> , 2013, 122, 3880-3880.	0.6	1
149	Diagnostic Features and 2-Hydroxyglutarate (2-HG) Levels Among Acute Myeloid Leukemia (AML) Patients with and without Isocitrate Dehydrogenase (IDH) Mutations. <i>Blood</i> , 2014, 124, 1045-1045.	0.6	1
150	Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort. <i>Blood</i> , 2018, 132, 1428-1428.	0.6	1
151	Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database. <i>Blood</i> , 2018, 132, 3999-3999.	0.6	1
152	Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an <i>IDH1</i> or <i>IDH2</i> Mutation. <i>Blood</i> , 2021, 138, 1276-1276.	0.6	1
153	Evaluating Venetoclax Treatment Duration When Combined with Hypomethylating Agents in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. <i>Blood</i> , 2021, 138, 4412-4412.	0.6	1
154	Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 41-42.	0.6	1
155	Post-Traumatic Stress Disorder (PTSD) Symptoms in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 44-45.	0.6	1
156	A Phase 1 Study of Sea-CD70 in Myeloid Malignancies. <i>Blood</i> , 2020, 136, 23-24.	0.6	1
157	Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults. <i>Blood</i> , 2020, 136, 41-42.	0.6	1
158	Acute myeloid leukemia in a patient with constitutional 47,XXY karyotype. <i>Leukemia Research Reports</i> , 2015, 4, 28-30.	0.2	0
159	In Reply. <i>Oncologist</i> , 2016, 21, 1026-1026.	1.9	0
160	Inhibition Of Lyn and Syk By Treatment With Dasatinib, Fludarabine, and Rituximab Correlates With Apoptosis and Clinical Response In Patients With Relapsed CLL. <i>Blood</i> , 2013, 122, 5300-5300.	0.6	0
161	<i>IDH1</i> Splicing Alterations in Patients with AML and Their Relationship to Blood 2HG Levels. <i>Blood</i> , 2014, 124, 1060-1060.	0.6	0
162	Serum Uric Acid Levels during Allogeneic Hematopoietic Cell Transplantation and Subsequent Graft Versus Host Disease. <i>Blood</i> , 2014, 124, 2493-2493.	0.6	0

#	ARTICLE	IF	CITATIONS
163	The Impact of Insurance Status at Diagnosis on Overall Survival in Chronic Myeloid Leukemia: A Population-Based Analysis. <i>Blood</i> , 2015, 126, 631-631.	0.6	0
164	Comparison of Age at Diagnosis, Cytogenetic Risk, and Overall Survival Between Acute Myeloid Leukemia Patients of White and South Asian Race/Ethnicity in the United States. <i>Blood</i> , 2015, 126, 3753-3753.	0.6	0
165	Health Care Utilization and End of Life Care for Older Patients with Acute Myeloid Leukemia Receiving Supportive Care Alone. <i>Blood</i> , 2015, 126, 2126-2126.	0.6	0
166	A Phase 1 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Ara-C in Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2550-2550.	0.6	0
167	Potentially Avoidable Hospitalizations in Older Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 3310-3310.	0.6	0
168	Examination of Phosphoprotein Targets in Timed Samples from Patients with RAS-Mutated AML during Concurrent Treatment with Alpelisib and Binimetinib on the Phase Ib Clinical Trial CMEK162X2109. <i>Blood</i> , 2016, 128, 2749-2749.	0.6	0
169	A Retrospective Analysis of Incident Cardiac and Neurological Co-Morbidity Following Treatment of Acute Promyelocytic Leukemia. <i>Blood</i> , 2016, 128, 3994-3994.	0.6	0
170	The Impact of Regional Cardiovascular Care Outcomes on Survival and Cardiovascular-Specific Mortality in Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 5984-5984.	0.6	0
171	Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults. <i>Blood</i> , 2018, 132, 2704-2704.	0.6	0
172	The Effect of JAK 1/2 Inhibitors on Outcomes of Allogeneic Stem Cell Transplantation for Patients with Myelofibrosis. <i>Blood</i> , 2018, 132, 5784-5784.	0.6	0
173	Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Myeloid Leukemia in Older Adults. <i>Blood</i> , 2018, 132, 4059-4059.	0.6	0
174	Clinical Outcomes Following Frontline Chemotherapy for Patients with Myeloid Malignancies Harboring Splicing Factor Mutations. <i>Blood</i> , 2018, 132, 4364-4364.	0.6	0
175	Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 2291-2291.	0.6	0
176	Outcomes for Older Patients with Acute Myeloid Leukemia after Admission to the Intensive Care Unit (ICU). <i>Blood</i> , 2018, 132, 4750-4750.	0.6	0
177	Efficacy of Lenalidomide and Bortezomib for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 4587-4587.	0.6	0
178	Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1431-1431.	0.6	0
179	Targeted FGFR Inhibition Results in Hematologic and Cytogenetic Remission in a Myeloid Neoplasm Driven By a Novel PCMI-FGFR1 Fusion: Data from an Expanded Access Program. <i>Blood</i> , 2019, 134, 5371-5371.	0.6	0
180	Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of the Day 14 Bone Marrow Biopsy. <i>Blood</i> , 2019, 134, 1442-1442.	0.6	0

#	ARTICLE	IF	CITATIONS
181	The Associations between Coping Strategy Use and Patient-Reported Outcomes in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4131-4131.	0.6	0
182	Increased Risk of Thrombosis in Patients with Myeloproliferative Neoplasms Compared with the General Population Hospitalized with COVID-19. <i>Blood</i> , 2021, 138, 1508-1508.	0.6	0
183	Factors Associated with High Healthcare Utilization at the End-of-Life (EOL) for Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 24-25.	0.6	0
184	Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults. <i>Blood</i> , 2020, 136, 7-8.	0.6	0
185	Rates of Thrombotic Events in Hypereosinophilic Syndrome and the Effect of Molecular Aberrations in Thrombotic Risk. <i>Blood</i> , 2020, 136, 14-14.	0.6	0
186	A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies. <i>Blood</i> , 2020, 136, 5-6.	0.6	0
187	Multi-Site Randomized Trial of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 26-27.	0.6	0
188	Outcomes of IDH1- and IDH2-Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2020, 136, 2-3.	0.6	0
189	A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies. <i>EJHaem</i> , 0, , .	0.4	0